Mallinckrodt (MNK) Given a $27.00 Price Target by Wells Fargo & Co Analysts

Share on StockTwits

Wells Fargo & Co set a $27.00 target price on Mallinckrodt (NYSE:MNK) in a report released on Tuesday morning. The firm currently has a hold rating on the stock.

A number of other equities research analysts also recently weighed in on MNK. Raymond James downgraded Mallinckrodt from an outperform rating to a market perform rating and set a $58.00 price target for the company. in a research note on Wednesday, August 8th. They noted that the move was a valuation call. Mizuho reaffirmed a hold rating and set a $27.00 price target on shares of Mallinckrodt in a research note on Tuesday. Zacks Investment Research downgraded Mallinckrodt from a buy rating to a hold rating in a research note on Friday, August 24th. Morgan Stanley raised their price target on Mallinckrodt from $14.00 to $35.00 and gave the stock an equal weight rating in a research note on Friday, August 17th. Finally, Barclays raised their price target on Mallinckrodt from $12.00 to $20.00 and gave the stock an underweight rating in a research note on Wednesday, August 8th. Four equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and four have assigned a buy rating to the company. Mallinckrodt has a consensus rating of Hold and a consensus price target of $32.53.

NYSE MNK traded down $0.28 during trading on Tuesday, reaching $30.89. 2,026,671 shares of the company’s stock were exchanged, compared to its average volume of 1,767,710. Mallinckrodt has a fifty-two week low of $11.65 and a fifty-two week high of $36.65. The firm has a market capitalization of $2.56 billion, a PE ratio of 4.12, a PEG ratio of 0.42 and a beta of 1.71. The company has a current ratio of 2.21, a quick ratio of 2.06 and a debt-to-equity ratio of 0.93.

Mallinckrodt (NYSE:MNK) last announced its quarterly earnings data on Tuesday, November 6th. The company reported $2.10 EPS for the quarter, topping the Zacks’ consensus estimate of $1.79 by $0.31. Mallinckrodt had a return on equity of 9.60% and a net margin of 65.24%. The firm had revenue of $640.00 million during the quarter, compared to analyst estimates of $634.38 million. During the same period last year, the company posted $1.97 EPS. The business’s quarterly revenue was up 6.6% compared to the same quarter last year. Research analysts anticipate that Mallinckrodt will post 7.09 EPS for the current year.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Advisors Preferred LLC grew its holdings in Mallinckrodt by 493.9% in the 2nd quarter. Advisors Preferred LLC now owns 10,512 shares of the company’s stock valued at $196,000 after buying an additional 8,742 shares during the last quarter. Balasa Dinverno & Foltz LLC acquired a new stake in Mallinckrodt in the 2nd quarter valued at approximately $200,000. Janus Henderson Group PLC acquired a new stake in Mallinckrodt in the 2nd quarter valued at approximately $237,000. Crossmark Global Holdings Inc. acquired a new stake in Mallinckrodt in the 3rd quarter valued at approximately $247,000. Finally, Bronfman E.L. Rothschild L.P. grew its holdings in Mallinckrodt by 46.7% in the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 15,238 shares of the company’s stock valued at $284,000 after buying an additional 4,853 shares during the last quarter.

About Mallinckrodt

Mallinckrodt public limited company develops, manufactures, markets, and distributes branded pharmaceutical products in Canada and the European Union, as well as in Latin American, the Middle Eastern, African, and the Asia-Pacific regions. The company markets branded pharmaceutical products for autoimmune and rare diseases in the specialty areas of neurology, rheumatology, nephrology, ophthalmology, and pulmonology; and immunotherapy and neonatal respiratory critical care therapies, as well as analgesics and gastrointestinal products.

Read More: How is the S&P 500 index different from the DJIA?

Analyst Recommendations for Mallinckrodt (NYSE:MNK)

Receive News & Ratings for Mallinckrodt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply